Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei

Neurobiology of Disease

Volumn 13, Issue 1, 2003, Pages 46-54

  Meissner, Wassilios ^a   Dovero, Sandra ^a   Bioulac, Bernard ^a   Gross, Christian E ^a   Bezard, Erwan ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYTOCHROME C OXIDASE; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; MESSENGER RNA; NEUROPEPTIDE; PREPROENKEPHALIN; PREPROTACHYKININ;

ANIMAL EXPERIMENT; ARTICLE; BASAL GANGLION; BRAIN METABOLISM; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; ENZYME METABOLISM; GABAERGIC TRANSMISSION; GENE EXPRESSION REGULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REGULATORY MECHANISM;

EID: 0037723832     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-9961(03)00011-1     Document Type: Article

References (45)

1. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits neural substrates of parallel processing . Trends Neurosci. 13:1990;266-271.
2. Asselin M.C., Soghomonian J.J., Côté P.Y., Parent A. Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys. Neuroreport. 5:1994;2137-2140.
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20:1973;415-455.
4. Bezard E., Boraud T., Bioulac B., Gross C. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur. J. Neurosci. 11:1999;2167-2170.
5. Bezard, E., Crossman, A.R., Gross, C.E., Brotchie, J.M., 2001a. Structures outside the basal ganglia may compensate for dopamine loss in the pre-symptomatic stages of Parkinson's disease. FASEB J. 10.1096, fj.00-0637fje.
6. Bezard E., Dovero S., Bioulac B., Gross C. Effect of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp. Neurol. 148:1997;288-292.
7. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. J. Neurosci. 21:2001;6853-6861.
8. Bezard E., Gross C.E. Compensatory mechanisms in experimental and human parkinsonism towards a dynamic approach . Prog. Neurobiol. 55:1998;93-116.
9. Bezard E., Jaber M., Gonon F., Boireau A., Bloch B., Gross C. Adaptive changes in nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur. J. Neurosci. 12:2000;2892-2900.
10. Bezard E., Ravenscroft P., Gross C.E., Crossman A.R., Brotchie J.M. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Neurobiol. Dis. 8:2001;343-350.
11. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA. 94:1997;3363-3367.
12. Bordet R., Ridray S., Schwartz J.C., Sokoloff P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-OHDA-lesioned rats. Eur. J. Neurosci. 12:2000;2117-2123.
13. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10:1998;2694-2706.
14. Dal Toso R., Sommer B., Ewert M., Herb A., Pritchett D.B., Bach A., Shivers B.D., Seeburg P.H. The dopamine D2 receptor two molecular forms generated by alternative splicing . EMBO J. 8:1989;4025-4034.
15. Dearry A., Gingrich J.A., Falardeau P., Fremeau R.T. Jr., Bates M.D., Caron M.G. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature. 347:1990;72-76.
16. Ehringer H., Hornykiewiez O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38:1960;1236-1239.
17. Emond P., Garreau L., Chalon S., Boazi M., Caillet M., Bricard J., Frangin Y., Mauclaire L., Besnard J.C., Guilloteau D. Synthesis and ligand binding of nortropane derivativesN-substituted 2b-carboxymethoxy-3b-(4′-iodophenyl)nortropane and N-(3-iodoprop-2E-enyl)-2b-carboxymethoxy-3b-(3′,4′-disubstituted phenyl) nortropane new high-affinity and selective compounds for the dopamine transporter . J. Med. Chem. 40:1997;1366-1372.
18. Franklin K.B., Paxinos G. The mouse brain in stereotaxic coordinates. 1997;Academic Press, Orlando, USA.
19. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
20. German D.C., Nelson E.L., Liang C.-L., Speciale S.G., Sinton C.M., Sonsalla P.K. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9, and A10 dopaminergic neurons in the mouse. Neurodegeneration. 5:1996;299-312.
21. Gonzalez-Lima F., Garrosa M. Quantitative histochemistry of cytochrome oxidase in rat brain. Neurosci. Lett. 123:1991;251-253.
22. Gross, C.E., Ravenscroft, P., Dovero, S., Jaber, M., Bioulac, B., Bezard, E., 2003. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J. Neurochem. 84, 1246-1255.
23. Gudehithlu K.P., Duchemin A.M., Tejwani G.A., Neff N.H., Hadjiconstantinou M. Preproenkephalin mRNA and methionine-enkephalin increase in mouse striatum after 1-methyl-1,2,3,6-tetrahydropyridine treatment. J. Neurochem. 56:1991;1043-1048.
24. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature. 411:2001;86-89.
25. Guilloteau D., Emond P., Baulieu J.L., Garreau L., Frangin Y., Pourcelot L., Mauclaire L., Besnard J.-C., Chalon S. Exploration of the dopamine transporter in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2b-carbomethoxy-3b-(4′-methylphenyl) nortropane (PE2I) . Nucl. Med. Biol. 25:1998;331-337.
26. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., Moller A., Nielsen K., Nyengaard J.R., Pakkenberg B., Sorensen F.B., Vesterby A., West M.J. The new stereological tools disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis . APMIS. 96:1988;857-881.
27. Heikkila R.E., Sonsalla P. The MPTP-treated mouse as a model of parkinsonism how good is it? Neurochem . Int. 20:1991;299-303.
28. Henry B., Crossman A.R., Brotchie J.M. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 155:1999;204-220.
29. Herrero M.T., Augood S.J., Hirsch E.C., Javoy-Agid F., Luquin M.R., Agid Y., Obeso J.A., Emson P.C. Effects of L-Dopa on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience. 68:1995;1189-1198.
30. Hevner R.F., Wong-Riley M.T. Brain cytochrome oxidase purification, antibody production, and immunohistochemical/histochemical correlations in the CNS . J. Neurosci. 9:1989;3884-3898.
31. Hevner R.F., Wong-Riley M.T. Regulation of cytochrome oxidase protein levels by functional activity in the macaque monkey visual system. J. Neurosci. 10:1990;1331-1340.
32. Innis R.B., Andrade R., Aghajanian G.K. Substance K excites dopaminergic and non-dopaminergic neurons in rat substantia nigra. Brain Res. 335:1985;381-383.
33. Maneuf Y.P., Mitchell I.J., Crossman A.R., Brotchie J.M. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp. Neurol. 125:1994;65-71.
34. Morissette M., Grondin R., Goulet M., Bedard P.J., Di Paolo T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D-1 or D-2 receptor agonists. J. Neurochem. 72:1999;682-692.
35. Morrish P.K., Rakshi J.S., Bailey D.L., Sawle G.V., Brooks D.J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J. Neurol. Neurosurg. Psychiatry. 64:1998;314-349.
36. Nawa H., Kotani H., Nakanishi S. Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing. Nature. 312:1984;729-734.
37. Pinnock R.D., Dray A. Differential sensitivity of presumed dopaminergic and non-dopaminergic neurones in rat substantia nigra to electrophoretically applied substance P. Neurosci. Lett. 29:1982;153-158.
38. Soghomonian J.J., Laprade N. Glutamate decarboxylase (GAD67 and GAD65) gene expression is increased in a subpopulation of neurons in the putamen of parkinsonian monkeys. Synapse. 27:1997;122-132.
39. Tang F., Costa E., Schwartz J.P. Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2 to 3 weeks. Proc. Natl. Acad. Sci. USA. 80:1983;3841-3844.
40. Theoret H., Boire D., Herbin M., Ptito M. Stereological evaluation of substantia nigra cell number in normal and hemispherectomized monkeys. Brain Res. 835:1999;354-359.
41. Thornburg J.E., Moore K.E. Supersensitivity to dopamine agonists following unilateral, 6-hydroxydopamine-induced striatal lesions in mice. J. Pharmacol. Exp. Ther. 192:1975;42-49.
42. Vila M., Perier C., Feger J., Yelnik J., Faucheux B., Ruberg M., Raisman-Vozari R., Agid Y., Hirsch E.C. Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. Eur. J. Neurosci. 12:2000;337-344.
43. West M.J. Stereological methods for estimating the total number of neurons and synapses issues of precision and bias . Trends Neurosci. 22:1999;51-61.
44. West M.J., Gundersen H.J. Unbiased stereological estimation of the number of neurons in the human hippocampus. J. Comp. Neurol. 296:1990;1-22.
45. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons some clinical and basic implications . Trends Neurosci. 13:1990;290-296.